Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2017 1
2018 2
2019 3
2020 4
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Targeted Radiotherapeutics from 'Bench-to-Bedside'.
Müller C, Béhé M, Geistlich S, van der Meulen NP, Schibli R. Müller C, et al. Among authors: geistlich s. Chimia (Aarau). 2020 Dec 23;74(12):939-945. doi: 10.2533/chimia.2020.939. Chimia (Aarau). 2020. PMID: 33357286 Free article. Review.
Antibody-guided Molecular Imaging of Aspergillus Lung Infections in Leukemia Patients.
Schwenck J, Maurer A, Beziere N, Fiz F, Boschetti F, Geistlich S, Seyfried D, Gunzer M, Reischl G, Wehrmüller J, Ehrlichmann W, Horger M, Gatidis S, Davies G, Vogel W, la Fougere C, Pichler BJ, Thornton C. Schwenck J, et al. Among authors: geistlich s. J Nucl Med. 2022 Jul 21:jnumed.121.263251. doi: 10.2967/jnumed.121.263251. Online ahead of print. J Nucl Med. 2022. PMID: 35863897 Free article. No abstract available.
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M. Sauter AW, et al. Among authors: geistlich s. J Nucl Med. 2019 Mar;60(3):393-399. doi: 10.2967/jnumed.118.207845. Epub 2018 Jul 12. J Nucl Med. 2019. PMID: 30002107 Free article.
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.
Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP, Geistlich S, Borgna F, Fani M, Bernhardt P, van der Meulen NP, Müller C, Schibli R, Wild D. Fricke J, et al. Among authors: geistlich s. Eur J Nucl Med Mol Imaging. 2024 Mar 7. doi: 10.1007/s00259-024-06641-w. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38448550 No abstract available.
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.
Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D. Rottenburger C, et al. Among authors: geistlich s. J Nucl Med. 2020 Apr;61(4):520-526. doi: 10.2967/jnumed.119.233031. Epub 2019 Sep 13. J Nucl Med. 2020. PMID: 31519804 Free PMC article. Clinical Trial.
12 results